Experience with intermediate-dose (110-120 mg/m2) epirubicin.

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Advanced malignancies pose significant treatment challenges.
• Epirubicin is an anthracycline chemotherapy agent used in various cancers.
• Understanding dose-limiting toxicities and efficacy is crucial for optimizing cancer treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of escalating doses of epirubicin in patients with advanced malignancies.
• To identify dose-limiting toxicities associated with epirubicin administration.
• To explore preliminary antitumor activity of epirubicin in specific cancer types.

Main Methods:

• A phase I/II study involving 23 patients with advanced malignancies.
• Escalating intravenous doses of epirubicin (100-120 mg/m2) administered every 3 weeks.
• Assessment of toxicity, including mucositis, myelotoxicity, nausea, vomiting, alopecia, and cardiovascular effects.
• Evaluation of treatment response using complete and partial response criteria.

Main Results:

• Mucositis (grade II/III) occurred in 47% of courses at 120 mg/m2, compared to 15% at 115 mg/m2.
• Leukopenia was the primary myelotoxicity, with a median white blood cell nadir of 1.9 x 10(9)/l.
• Complete responses were observed in two patients (penile and gastric carcinoma), and partial responses in six (including breast cancer and sarcoma).
• No renal, hepatic, or cardiac toxicity was noted; one fatal coronary thrombosis occurred.
• Thrombophlebitis occurred in 4 patients, unrelated to dose.

Conclusions:

• Intermediate-dose epirubicin (up to 120 mg/m2) is generally well-tolerated in advanced malignancies.
• Mucositis emerges as a dose-limiting toxicity at 120 mg/m2.
• Epirubicin demonstrates promising preliminary activity in gastric cancer, breast cancer, and sarcomas.